Purpose: We intend to use big data and machine learning techniques to improve the models to better predict and maintain response to infliximab therapy.
Primary Outcome: Identify predictors for primary non-response and secondary loss of response.
Secondary Outcome: Determine significant time varying features for effective treatment time.
Funding Source: Eunice Kennedy Shriver National Institute of Child Health and Human Development under award number 5T32HD069054 (Cincinnati Training Program in Pediatric Clinical & Developmental Pharmacology; Vinks, Program director).
Study Period: 2020-2022
Recruitment Status: This study makes use of existing data in the ICN registry. No patient recruitment is occurring at this time.
Contact: Ye Xiong